Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Not yet recruiting × Standard of Care × Endocrine × Clear all

Phase

Status

Completed 3 Not yet recruiting 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 7 Gastrointestinal 5 Tumor-Agnostic 3 Head & Neck 3 Thoracic 2 Lymphoid 2 Genitourinary 2 Dermatologic 2 Plasma cell 1 Other solid neoplasm 1 Other hematologic neoplasm 1 Other 1 Endocrine 1 CNS 1

Conditions

Carcinoma, Neuroendocrine 1

Interventions

Observation 2 zimberelimab 1 trametinib 1 lutetium Lu 177 dotatate 1 fluorocholine 1 dabrafenib 1 apatinib 1 Surveys and Questionnaires 1 Standard of Care 1 Radiomics 1 Radiation 1 Positron Emission Tomography Computed Tomography 1 Mitoxantrone 1 Injections 1 Engineering 1 Endoscopic Mucosal Resection 1 Cisplatin 1 Carboplatin 1 Bromocriptine 1 Biological Products 1 Adrenalectomy 1 3-(3'-adamantan-1-yl-4'-methoxybiphenyl-4-yl)-2-propenoic acid 1 2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07337447 2026-01-13

REWENEC 01

Hospices Civils de Lyon

Phase 2 Not yet recruiting

Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon ⚡